Effects of recombinant human endostatin on a human neuroblastoma xenograft

Citation
M. Kuroiwa et al., Effects of recombinant human endostatin on a human neuroblastoma xenograft, INT J MOL M, 8(4), 2001, pp. 391-396
Citations number
32
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Medical Research General Topics
Journal title
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
ISSN journal
1107-3756 → ACNP
Volume
8
Issue
4
Year of publication
2001
Pages
391 - 396
Database
ISI
SICI code
1107-3756(200110)8:4<391:EORHEO>2.0.ZU;2-2
Abstract
New antitumor agents must be added to the current neuroblastoma treatment r egimens to improve the clinical results. We investigated whether recombinan t human endostatin (rhEndostatin), an antiangiogenic agent, is effective ag ainst human neuroblastoma in the human neuroblastoma xenograft model design ated TNB9. When tumors on the back of nude mice grew to a weight of 90-95 m u, rhEndostatin 10 mg/kg/day was administered subcutaneously every day for 10 consecutive days. Mean relative tumor weight in mice administered rhEndo statin (n=5) was significantly less than that in controls (n=12) on days 2, 4, and 6 after the start of administration (p <0.01 on day 2, p <0.05 on d ays 4 and 6), and regression of tumor growth (T-RW<1.0) was marked on day 2 . The maximum inhibition rate (MIR) by rhEndostatin was 46.4%, indicating i nefficacy, but it may not be appropriate to apply Battelle Columbus Laborat ories criteria to this experimental model because rhEndostatin is a protein . After day 8, tumors in the experimental group increased in weight and wer e not statistically significantly different from those in controls. Recombi nant human endostatin was used in tumors in the arterial system of the mous e in this experiment because eventually rhEndostatin, not recombinant mouse endostatin, may be used to treat advanced neuroblastoma in the clinical se tting. The results show that there is little cross-reactivity of rhEndostat in with the human and mouse models and indicate that rhEndostatin could bec ome an effective agent for the treatment of human neuroblastoma.